Revenue (TTM)32.106B Gross Margin (TTM)65.48% Net Margin (TTM)4.55% Debt To Equity (MRQ)65.25% EVENTS Earnings Date05/07/2025(est) Ex Div Date09/30/2024 Div Amount0.3261 Split Date- Split Factor-Content From Our Affiliates CHMP gives positive opinion on variation to marketing authorization...
Pink Current Info |$USD | TKPHF Analysis Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns Investing Groups Covering TKPHF DIY Value Investing 4.8 Chris Lau Themes: Value Latest on TKPHF:The Week Ahead Starting Aug 15, 2022 ...
The company is building strong momentum with its high-value, late-stage programs. The transformative value these programs can deliver to patients, as well as the significant revenue potential through 2030 and beyond, were presented at the R&D Day event held in December 2024. Among the multiple l...
Reported revenue, atJPY 2,427.5 billion(~$23.5B), was impacted primarily by foreign exchange and divestitures, however Takeda delivered year-to-dateunderlying revenue growthof 1.1% in the third quarter of FY2020, which was driven by strong growth in ENTYVIO, TAKHZYRO, and Immunoglo...
TAK Revenue Sorry, this data cannot be displayed at the moment. TAK Earnings Per Share More On Earnings » Earnings Estimates FY EPS YoY PE Sales YoY 2025 0.36 +20.76% 38.74 $30.30B +690.90% 2026 0.54 +50.61% 25.73 $30.13B -0.58% 2027 0.56 +3.15% 24.94 $30.43B +1.00% More On Ear...
Takeda announced strong financial results for the first quarter of fiscal year 2023. Takeda chief financial officer, Costa Saroukos, commented: “Our Growth & Launch Products continued to drive revenue growth in the first quarter of FY2023, contributing
− Delivered H1 Year-Over-Year Growth in Reported Revenue of +12.8% and Underlying Revenue of +6.8% − 14 Global Brands Represent 42% of Total Core Revenue with +11.4% Underlying Growth in H1; Further Acceleration Expected through H2 ...
in December 2021, with 87% of U.S. transplant centers having initiated therapy with at least one patient. Plasma-Derived Therapies (PDT) Immunology, with 502.4 billion yen in reported revenue, delivered outstanding growth of +18% on a CER...
The Pharmacia merger has expanded ITLT’s scope in establishing direction, strategy, and alignment of IT with the business needs. In place of 25 pharmaceutical products, we now have more than 1000 such products increasing our product portfolio, revenue, and geographical reach. The current ITLT ...
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion ...